Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

Phase 3

Not yet recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Sitafloxacin
Drug: Rifampin
Drug: Pyrazinamide
Drug: SMZ/TMP
Drug: Rifapentine
Drug: Ethambutol
Drug: Isoniazid
Drug: Moxifloxacin

First Posted Date: 2022-07-12

Last Posted Date: 2022-07-12

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 620

Registration Number: NCT05454345

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aticaprant Supratherapeutic Dose
Drug: Aticaprant Therapeutic Dose
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2022-05-24

Last Posted Date: 2023-10-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 60

Registration Number: NCT05387759

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Brensocatib
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2022-05-02

Last Posted Date: 2023-03-27

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 48

Registration Number: NCT05355935

Locations: 🇺🇸
USA001, Madison, Wisconsin, United States

A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: Soticlestat
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2022-04-04

Last Posted Date: 2022-11-14

Lead Sponsor: Takeda

Registration Number: NCT05309902

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: MT-7117
Drug: moxifloxacin
Drug: Placebo

First Posted Date: 2022-02-15

Last Posted Date: 2023-05-15

Lead Sponsor: Mitsubishi Tanabe Pharma America Inc.

Target Recruit Count: 29

Registration Number: NCT05241535

Locations: 🇺🇸
Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States
🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CTP-543
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2022-01-14

Last Posted Date: 2022-03-04

Lead Sponsor: Concert Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT05192369

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Active, not recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Moxifloxacin

First Posted Date: 2021-09-16

Last Posted Date: 2024-01-05

Lead Sponsor: Tuberculosis Research Centre, India

Target Recruit Count: 550

Registration Number: NCT05047055

Locations: 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin
Drug: Setmelanotide
Drug: Oral Placebo
Drug: SC Placebo

First Posted Date: 2021-09-16

Last Posted Date: 2024-05-03

Lead Sponsor: Rhythm Pharmaceuticals, Inc.

Target Recruit Count: 77

Registration Number: NCT05046132

Locations: 🇺🇸
Parexel Early Phase Clinical Unit (Los Angeles), Glendale, California, United States

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Danicopan
Drug: Moxifloxacin-matching Placebo
Drug: Danicopan-matching placebo
Drug: Moxifloxacin

First Posted Date: 2021-08-23

Last Posted Date: 2021-08-23

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 33

Registration Number: NCT05016206

Locations: 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Cedazuridine
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2021-07-08

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT04953923

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy